Ondine Biomedical's Steriwave Nasal Photodisinfection Reduces Spine Surgical Site Infections by 78% in Quebec Hospital
Why we think this is neutral
This RNS announcement provides an update on the successful deployment of Ondine Biomedical's Steriwave nasal photodisinfection technology in a Quebec hospital, leading to a significant reduction in surgical site infections for spine surgery patients. While the results are positive, the announcement does not contain any financial or trading updates, and therefore does not warrant a strong sentiment score.
Key Points
- Patients receiving Steriwave nasal decolonization exhibited a 78.8% lower SSI rate compared to the control group
- The Steriwave group experienced a 30% shorter average hospital stay, indicating enhanced patient recovery and optimized healthcare resources
- Based on an estimated cost of $50,000 per SSI, the return on the Steriwave investment was greater than $17 per $1 spent on the technology deployment
Summary
Ondine Biomedical's Steriwave nasal photodisinfection technology achieved a 78.8% reduction in surgical site infections (SSIs) for spine surgery patients at the University of Sherbrooke in Quebec. The study also found that patients treated with Steriwave had a 30% shorter average hospital stay. The findings reinforce the benefits of Ondine's innovative antimicrobial technology in improving patient outcomes and reducing healthcare costs.